Gladius Capital Management LP Increases Stock Holdings in Revvity, Inc. (NYSE:RVTY)

Gladius Capital Management LP increased its stake in Revvity, Inc. (NYSE:RVTY) by 85.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 430 shares of the company’s stock after acquiring an additional 198 shares during the quarter. Gladius Capital Management LP’s holdings in Revvity were worth $47,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in RVTY. Parkside Financial Bank & Trust acquired a new stake in shares of Revvity in the fourth quarter worth approximately $25,000. Benjamin F. Edwards & Company Inc. purchased a new position in Revvity in the 4th quarter valued at $27,000. CENTRAL TRUST Co acquired a new stake in Revvity during the 4th quarter worth $27,000. ORG Partners LLC purchased a new stake in shares of Revvity during the fourth quarter worth $32,000. Finally, JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Revvity in the fourth quarter valued at about $33,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Trading Up 1.5 %

Shares of Revvity stock traded up $1.51 during trading hours on Thursday, hitting $104.34. The company’s stock had a trading volume of 399,914 shares, compared to its average volume of 835,973. The firm has a fifty day moving average of $104.29 and a 200-day moving average of $101.30. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.23. The stock has a market cap of $12.89 billion, a price-to-earnings ratio of 86.23, a P/E/G ratio of 2.62 and a beta of 1.09. Revvity, Inc. has a twelve month low of $79.50 and a twelve month high of $131.96.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The company had revenue of $649.90 million for the quarter, compared to analysts’ expectations of $646.83 million. During the same quarter in the prior year, the company posted $1.01 earnings per share. Revvity’s revenue for the quarter was down 3.7% compared to the same quarter last year. Research analysts forecast that Revvity, Inc. will post 4.66 EPS for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Raymond James upped their price objective on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. UBS Group lowered Revvity from a “buy” rating to a “neutral” rating and upped their price target for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Barclays lifted their price objective on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. KeyCorp boosted their price objective on Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, Robert W. Baird raised their target price on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 30th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Revvity has a consensus rating of “Moderate Buy” and an average price target of $118.17.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.